Abstract:SUMMARY:Aim: Peritoneal matrix accumulation is a characteristic of peritoneal fibrosis (PF). Continuous ambulatory peritoneal dialysis (CAPD) patients with up‐regulation of transforming growth factor‐β1 (TGF‐β1) in their drained effluent show an increased risk of PF. Inhibition of TGF‐β1 expression in human peritoneal mesothelial cells (HPMC) may provide a potential treatment for PF. Peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) agonists are increasingly used in patients with diabetes, but their effects on extracellular matrix (ECM) turnover are unknown. The aims of this study were to investigate the effects of the PPAR‐γ agonist troglitazone on TGF‐β1 expression and matrix production in HPMC.Methods: Human peritoneal mesothelial cells were cultured from human omentum by an enzyme digestion method, grown in a medium containing 30 mmol/L D‐glucose. TGF‐β1 expression and matrix production and turnover were measured in HPMC in the presence and absence of 15 µmol/L troglitazone. The mRNA expressions of TGF‐β1, Collagen I (Col I) and fibronectin (FN) were determined by semiquantification reverse‐transcriptive polymerase chain reaction (RT‐PCR). The protein of TGF‐β1 was determined by ELISA and proteins of Col I, FN were determined by western blot.Results: The mRNA expression and protein of TGF‐β1, Col I, FN were significantly increased in HPMC stimulated with 30 mmol/L D‐glucose compared to the control group with F12 media (P < 0.01), which was reversed in the presence of troglitazone (15 µmol/L). Obvious decrease of TGF‐β1 was found in troglitazone‐treated groups as compared to groups stimulated with GS (P < 0.05). Exposure of HPMC to troglitazone reduced collagen I secretion (P < 0.05), and fibronectin secretion (P < 0.05).Conclusion: Troglitazone reduce the expression of TGF‐β1 in HPMC stimulated by 30 mmol/L D‐glucose, and reduces ECM production. These studies suggest that the PPAR‐γ agonists may have a specific role in ameliorating the course of progressive peritoneal fibrosis under long‐term peritoneal dialysis states.

Troglitazone Inhibits Proliferation of GH3 Cell in Vitro

Troglitazone Inhibits Rat Pituitary Adenoma GH3 Cell Growth by Activating Peroxisome Proliferator-Activated Receptor-Gamma to Suppress Cyclin DI Transcription

Poster Session AP2: Cell Death and Survival

Troglitazone Inhibits Cell Proliferation by Attenuation of Epidermal Growth Factor Receptor Signaling Independent of Peroxisome Proliferator-Activated Receptor Γ

Effects of Troglitazone on the Proliferation and Differentiation of HepG2 Cells

Effect of Ligand Troglitazone on Peroxisome Proliferator-Activated Receptor Gamma Expression and Cellular Growth in Human Colon Cancer Cells

1 α ,25 (OH)2D3 inhibits proliferation of gastric cancer cell line by arresting cell cycle

Troglitazone Sensitizes Effect of Epirubicin on Breast Cancer Cells

[Effects of Pioglitazone on the Transdifferentiation and CTGF Expression of Renal Tubular Epithelial-Myofibroblast in Vitro].

Effect and Mechanism of Pioglitazone on Cell Growth in Human Gastric Cancer Cells

Effects of troglitazone on proliferation and apoptosis of BGC-823 cells

Anti-proliferation Effect of Troglitazone on NB4 Cells and Its Mechamsms of Action

A Marine Anthraquinone SZ-685C Inhibits Cell Proliferation and Induces Apoptosis in GH3 Cells

[Inhibitory Effects of Thiazolidinedione Upon Cytokine-Induced Apoptosis in Pancreatic Beta-Cell Line].

Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits glioma cell growth mediated by β-catenin

Anti-proliferation Effect of Peroxisome Proliferator-Activated Receptor Γ Agonist on Raji Cells and Its Mechanism

Troglitazone Induces Apoptosis in Gastric Cancer Cells Through the NAG-1 Pathway.

[Inhibitive Effect of Troglitazone on TGF-beta(1) and Fibronectin Expression in Human Peritoneal Mesothelial Cells].

Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells

[Effects of Peroxisome Proliferator-Activated Receptor-Gamma Ligand Troglitazone on Colon Cancer Cell Growth].

Troglitazone Inhibits Synthesis of Transforming Growth Factor-Beta1 and Reduces Matrix Production in Human Peritoneal Mesothelial Cells.